TABLE 2.
IC50 and TC50 of peptidyl-MIM candidates on chronic FIV-Petaluma-infected and uninfected CrFK cellsa
| Peptidyl-MIM candidate | IC50 (μM) | TC50 (μM) | In vitro therapeutic index |
|---|---|---|---|
| D4E1 | 0.46 | 5.90 | 12.83 |
| DC1 | 0.75 | 9.20 | 12.27 |
| D1D6 | 0.94 | 8.93 | 9.50 |
| 4C3 | 1.32 | 3.81 | 2.89 |
| 5F | 5.47 | 8.73 | 1.60 |
| 5C1 | 3.38 | 5.26 | 1.56 |
| D2B15 | 4.07 | 6.19 | 1.52 |
| D2A21 | 3.05 | 3.43 | 1.12 |
| 2A3 | 3.00 | 3.24 | 1.08 |
| D1A22 | 10.51 | 10.79 | 1.03 |
| D5C | 7.82 | 7.48 | 0.96 |
| 3A15 | 3.69 | 3.28 | 0.89 |
| DP1 | 7.07 | 5.17 | 0.73 |
| D1D2 | 8.71 | 5.87 | 0.67 |
| D4B | 2.85 | 0.92 | 0.32 |
| 5D | 3.37 | NA | NA |
a
Chronically infected CrFK cells were cultured with dilutions of peptidyl-MIM candidates as described in Materials and Method for 24 h. Values were calculated by plotting relative values of RT activity or cell toxicity against peptidyl-MIM concentrations modeled by linear regression analysis. Data are the means of triplicate samples. The in vitro therapeutic index was calculated as the TC50 of uninfected cells divided by the IC50 for each compound. The TC50 values of infected cells were not significantly different from those of uninfected cells (P = 0.250). NA, not available.